Background: Antiretroviral therapy improved the survival of patients with human immunodeficiency virus (HIV) infection. With increased life expectancy, HIV-infected patients increasingly are experiencing comorbidities, most notably cardiovascular risk factors (CRFs) and coronary heart disease (CHD).
Design: This study utilized a prospective, cross-sectional multicentre long-term design.
Methods: In 803 patients (82% male; mean age 44.2 ± 10.3 years) we evaluated the prevalence of CRFs and 10-year risk of CHD using the Framingham risk model. The presence of a risk factor was determined based on the guidelines of the National Cholesterol Education Program (NCEP ATP III), the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC7), and the German Society of Cardiology.
Results: The most common CRFs were smoking (51.2%), high triglycerides (39.0%), low high-density lipoprotein cholesterol (27.5 %) and high blood pressure (21.4%). In total, 60.3%, 21.6%, and 18.1% of patients were categorized as being at low (<10%), moderate (10–20%), and high (>20%) 10-year risk for CHD, respectively. In patients with hypertension, at least one antihypertensive drug was given in 91/163 (55.8%) patients. The percentage of patients on treatment with diabetes mellitus was 23/41 (56.1%). Anti-platelet therapy was prescribed to 42/102 (41.2%) patients with known CHD or CHD equivalent. In patients of moderate or high CHD risk there were more than 50% and 30% for LDL cholesterol and more than 60% and 40% for total cholesterol untreated.
Conclusions: The prevalence of CRFs remains high in an HIV-infected population. CRF management of HIV-infected patients deserves further improvement.
PalellaFJJrDelaneyKMMoormanACLovelessMOFuhrerJSattenGA. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med1998; 338(13): 853–860.
2.
SteinJHHadiganCMBrownTTChadwickEFeinbergJFriis-MollerN. Prevention strategies for cardiovascular disease in HIV-infected patients. Circulation2008; 118(2): e54–e60.
3.
MocroftALedergerberBKatlamaCKirkOReissPd’Arminio MonforteA. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet2003; 362(9377): 22–29.
4.
KoutkiaPGrinspoonS. HIV-associated lipodystrophy: pathogenesis, prognosis, treatment, and controversies. Annu Rev Med2004; 55: 303–317.
5.
SackoffJEHannaDBPfeifferMRTorianLV. Causes of death among persons with AIDS in the era of highly active antiretroviral therapy: New York City. Ann Intern Med2006; 145(6): 397–406.
6.
HoJEHsuePY. Cardiovascular manifestations of HIV infection. Heart2009; 95(14): 1193–1202.
7.
Friis-MollerNThiebautRReissPWeberRMonforteADDe WitS. Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study. Eur J Cardiovasc Prev Rehabil2010; 17(5): 491–501.
8.
GritzERVidrineDJLazevABAmickBC3rdArduinoRC. Smoking behavior in a low-income multiethnic HIV/AIDS population. Nicotine Tob Res2004; 6(1): 71–77.
9.
SavesMCheneGDucimetierePLeportCLe MoalGAmouyelP. Risk factors for coronary heart disease in patients treated for human immunodeficiency virus infection compared with the general population. Clin Infect Dis2003; 37(2): 292–298.
10.
BergersenBMSandvikLBruunJNTonstadS. Elevated Framingham risk score in HIV-positive patients on highly active antiretroviral therapy: results from a Norwegian study of 721 subjects. Eur J Clin Microbiol Infect Dis2004; 23(8): 625–630.
11.
GlassTRUngsedhapandCWolbersMWeberRVernazzaPLRickenbachM. Prevalence of risk factors for cardiovascular disease in HIV-infected patients over time: the Swiss HIV Cohort Study. HIV Med2006; 7(6): 404–410.
12.
NeumannTEsserSPotthoffAPankuweitSNeumannABreuckmannF. Prevalence and natural history of heart failure in outpatient HIV-infected subjects: rationale and design of the HIV-HEART study. Eur J Med Res2007; 12(6): 243–248.
13.
FriedewaldWTLevyRIFredricksonDS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem1972; 18(6): 499–502.
14.
Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP). Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA2001; 285(19): 2486–2497.
15.
ChobanianAVBakrisGLBlackHRCushmanWCGreenLAIzzoJLJ. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension2003; 42(6): 1206–1252.
16.
GohlkeHKublerWMathesPMeinertzTSchulerGGysanDB. [Policy paper on primary prevention of cardiovascular diseases. Current draft of 3/25/2003 issued by the Executive Committee of the German Society of Cardiology, Heart and Circulation Research. Edited by the Prevention Project Group on behalf of the Executive Committee]. Z Kardiol2003; 92(6): 522–523.
17.
MansiaGDe BackerGDominiczakACifkovaRFagardRGermanoG. 2007 ESH-ESC Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Blood Press2007; 16(3): 135–232.
18.
KaplanRCKingsleyLASharrettARLiXLazarJTienPC. Ten-year predicted coronary heart disease risk in HIV-infected men and women. Clin Infect Dis2007; 45(8): 1074–1081.
19.
Friis-MollerNReissPSabinCAWeberRMonforteAEl-SadrW. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med2007; 356(17): 1723–1735.
20.
BonnetFMorlatPCheneGMerciePNeauDChossatI. Causes of death among HIV-infected patients in the era of highly active antiretroviral therapy, Bordeaux, France, 1998⊟1999. HIV Med2002; 3(3): 195–199.
21.
WoodDDe BackerGFaergemanOGrahamIManciaGPyoralaK. Prevention of coronary heart disease in clinical practice. Summary of recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. Blood Press1998; 7(5–6): 262–269.
22.
TonstadSAndrew JohnstonJ. Cardiovascular risks associated with smoking: a review for clinicians. Eur J Cardiovasc Prev Rehabil2006; 13(4): 507–514.
23.
CalzaLManfrediRChiodoF. Hyperlipidaemia in patients with HIV-1 infection receiving highly active antiretroviral therapy: epidemiology, pathogenesis, clinical course and management. Int J Antimicrob Agents2003; 22(2): 89–99.
24.
HansenBRPetersenJHaugaardSBMadsbadSObelNSuzukiY. The prevalence of metabolic syndrome in Danish patients with HIV infection: the effect of antiretroviral therapy. HIV Med2009; 10(6): 378–387.
25.
da SilvaEFBarbaroG. New options in the treatment of lipid disorders in HIV-infected patients. Open AIDS J2009; 3: 31–37.
26.
FellayJBoubakerKLedergerberBBernasconiEFurrerHBattegayM. Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study. Lancet2001; 358(9290): 1322–1327.
27.
GrinspoonSKGrunfeldCKotlerDPCurrierJSLundgrenJDDubeMP. State of the science conference: Initiative to decrease cardiovascular risk and increase quality of care for patients living with HIV/AIDS: executive summary. Circulation2008; 118(2): 198–210.
28.
DubeMPSteinJHAbergJAFichtenbaumCJGerberJGTashimaKT. Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clin Infect Dis2003; 37(5): 613–627.
29.
LimaEMGualandroDMYuPCGiuliano IdeCMarquesACCalderaroD. Cardiovascular prevention in HIV patients: results from a successful intervention program. Atherosclerosis2009; 204(1): 229–232.
30.
KulasekaramRPetersBSWierzbickiAS. Dyslipidaemia and cardiovascular risk in HIV infection. Curr Med Res Opin2005; 21(11): 1717–1725.
31.
CarrAHudsonJChuahJMallalSLawMHoyJ. HIV protease inhibitor substitution in patients with lipodystrophy: a randomized, controlled, open-label, multicentre study. AIDS2001; 15(14): 1811–1822.
32.
CurrierJSLundgrenJD. Guidelines for managing cardiovascular risk: an evolving area. Curr Opin HIV AIDS2008; 3(3): 205–206.
33.
GohlkeHWinterMKaroffMHeldK. CARRISMA: a new tool to improve risk stratification and guidance of patients in cardiovascular risk management in primary prevention. Eur J Cardiovasc Prev Rehabil2007; 14(1): 141–148.
34.
AssmannGSchulteHCullenP. New and classical risk factors – the Munster heart study (PROCAM). Eur J Med Res1997; 2(6): 237–242.
35.
KnobelHJericoCMonteroMSorliMLVelatMGuelarA. Global cardiovascular risk in patients with HIV infection: concordance and differences in estimates according to three risk equations (Framingham, SCORE, and PROCAM). AIDS Patient Care STDS2007; 21(7): 452–457.
36.
LawMFriis-MollerNWeberRReissPThiebautRKirkO. Modelling the 3-year risk of myocardial infarction among participants in the Data Collection on Adverse Events of Anti-HIV Drugs (DAD) study. HIV Med2003; 4(1): 1–10.
